Description
TGX-221 is an inhibitor of p110β PI3K that exhibits anticancer and antithrombotic activities. TGX-221 decreases growth of cancer cells and lowers intracellular Ca2+ and Ca2+-transient currents in cardiac myocytes. TEST!!!!!!
TGX-221
Product ID T2792
Cas No. 663619-89-4
Purity
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 663619-89-4 |
|---|---|
| Formula Wt. | 364.44 |
| IUPAC Name | 9-(1-anilinoethyl)-7-methyl-2-morpholin-4-ylpyrido[1,2-a]pyrimidin-4-one |
| Solubility | DMSO 12 mg/mL (32.92 mM) Water Insoluble Ethanol Insoluble |
| Appearance | Light Yellow Powder |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| MSDS | |
|---|---|
| Info Sheet |
References
Graves BM, Simerly T, Li C, et al. Phosphoinositide-3-kinase/akt - dependent signaling is required for maintenance of [Ca(2+)](i), I(Ca), and Ca(2+) transients in HL-1 cardiomyocytes. J Biomed Sci. 2012 Jun 20;19:59. PMID: 22715995.
Bird JE, Smith PL, Bostwick JS, et al. Bleeding response induced by anti-thrombotic doses of a phosphoinositide 3-kinase (PI3K)-β inhibitor in mice. Thromb Res. 2011 Jun;127(6):560-4. PMID: 21396684.
Lu XY, Ciraolo E, Stefenia R, et al. Sustained release of PI3K inhibitor from PHA nanoparticles and in vitro growth inhibition of cancer cell lines. Appl Microbiol Biotechnol. 2011 Mar;89(5):1423-33. MID: 21286711.